| Title |
Which Target Blood Pressure in Year 2018? Evidence from Recent Clinical Trials
|
|---|---|
| Published in |
High Blood Pressure & Cardiovascular Prevention, April 2018
|
| DOI | 10.1007/s40292-018-0258-z |
| Pubmed ID | |
| Authors |
Sondre Heimark, Julian E. Mariampillai, Krzysztof Narkiewicz, Peter M. Nilsson, Sverre E. Kjeldsen |
| Abstract |
The Systolic Blood Pressure Intervention Trial (SPRINT) suggested a favourable effect of lowering blood pressure to < 120/80 mmHg in high-risk hypertensive patients; however, new American guidelines in 2017 have not followed SPRINT but lowered its recommended treatment target to < 130/80 mmHg. We aimed to review the latest research from large randomised controlled trials and observational analyses in order to investigate the evidence for new treatment targets. We assessed recent data from the Action to Control Cardiovascular Risk in Diabetes Blood Pressure (ACCORD) study, the International Verapamil-Trandolapril Study (INVEST), the Telmisartan, Ramipril or Both in Patients at High Risk for Vascular Events trial (ONTARGET)/the Telmisartan Randomised AssessmenNt Study in aCE iNtolerant participants with cardiovascular Disease (TRANSCEND) study and The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study. These studies confirm a positive effect on cardiovascular protection with blood pressure lowering treatment to between 120-140 mmHg in patients with and without diabetes, but no additional effect of lowering blood pressure to < 120 mmHg; possibly too aggressive treatment may increase both cardiovascular morbidity and mortality. Thus, a target blood pressure < 130/80 mmHg appears appropriate in most high-risk hypertensive patients. Additionally, early and sustained BP control below this target is required for optimal cardiovascular protection. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 5 | 19% |
| Researcher | 4 | 15% |
| Student > Bachelor | 3 | 12% |
| Student > Doctoral Student | 2 | 8% |
| Student > Master | 2 | 8% |
| Other | 4 | 15% |
| Unknown | 6 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 58% |
| Nursing and Health Professions | 2 | 8% |
| Immunology and Microbiology | 1 | 4% |
| Psychology | 1 | 4% |
| Neuroscience | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 6 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2018.
All research outputs
#14,852,402
of 23,043,346 outputs
Outputs from High Blood Pressure & Cardiovascular Prevention
#115
of 248 outputs
Outputs of similar age
#177,700
of 296,868 outputs
Outputs of similar age from High Blood Pressure & Cardiovascular Prevention
#4
of 6 outputs
Altmetric has tracked 23,043,346 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 248 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 296,868 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.